Myasthenia Gravis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Myasthenia Gravis – Pipeline Review, H1 2017’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis

The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects

The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achillion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Apellis Pharmaceuticals Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

HanAll Biopharma Co Ltd

Karus Therapeutics Ltd

Millennium Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Ra Pharmaceuticals Inc

Regenesance BV

Shire Plc

Toleranzia AB

UCB SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myasthenia Gravis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myasthenia Gravis - Companies Involved in Therapeutics Development

Achillion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Apellis Pharmaceuticals Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

HanAll Biopharma Co Ltd

Karus Therapeutics Ltd

Millennium Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Ra Pharmaceuticals Inc

Regenesance BV

Shire Plc

Toleranzia AB

UCB SA

Myasthenia Gravis - Drug Profiles

ACT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amifampridine phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARGX-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVMG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KA-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Regenemab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)

Jan 06, 2017: argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016

Dec 01, 2016: argenx to provide update on ARGX-113 during American Society of Hematology Annual Meeting

Sep 30, 2016: Toleranzia completes Eurostars project according to plan and postpones start of clinical study

Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York

Sep 02, 2016: Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis

Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress

Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis

Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe

May 29, 2015: Double recognition of Toleranzia

Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis

Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund

Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Myasthenia Gravis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Myasthenia Gravis – Pipeline by Achillion Pharmaceuticals Inc, H1 2017

Myasthenia Gravis – Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Myasthenia Gravis – Pipeline by Alpha Cancer Technologies Inc, H1 2017

Myasthenia Gravis – Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Myasthenia Gravis – Pipeline by arGEN-X BV, H1 2017

Myasthenia Gravis – Pipeline by BioMarin Pharmaceutical Inc, H1 2017

Myasthenia Gravis – Pipeline by CuraVac Inc, H1 2017

Myasthenia Gravis – Pipeline by GlaxoSmithKline Plc, H1 2017

Myasthenia Gravis – Pipeline by Grifols SA, H1 2017

Myasthenia Gravis – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Myasthenia Gravis – Pipeline by Karus Therapeutics Ltd, H1 2017

Myasthenia Gravis – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Myasthenia Gravis – Pipeline by Neurotune AG, H1 2017

Myasthenia Gravis – Pipeline by Novartis AG, H1 2017

Myasthenia Gravis – Pipeline by Pfizer Inc, H1 2017

Myasthenia Gravis – Pipeline by Ra Pharmaceuticals Inc, H1 2017

Myasthenia Gravis – Pipeline by Regenesance BV, H1 2017

Myasthenia Gravis – Pipeline by Shire Plc, H1 2017

Myasthenia Gravis – Pipeline by Toleranzia AB, H1 2017

Myasthenia Gravis – Pipeline by UCB SA, H1 2017

Myasthenia Gravis – Dormant Projects, H1 2017

Myasthenia Gravis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Myasthenia Gravis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports